| I N TR ODU C TI ON
Chronic enteropathy (CE) is a common condition in dogs. 1 Causes of CE can include adverse reaction to food, apparent antibiotic responsive diarrhea (ARD) and putative idiopathic inflammatory bowel disease (IBD), with these disorders best diagnosed retrospectively, by exclusion of other causes and response to treatment. 1, 2 As histopathological diagnosis does not reliably distinguish different causes of CE, determining the best treatment is currently undertaken on a trial-and-error basis. 1, 3 Further, outcomes for individuals vary widely and are difficult to predict, with some dogs responding to one treatment or another, and others responding poorly. 2 As a result, there is a need for novel tests that predict the best treatment and help to determine the likely outcome. Unfortunately, despite recent investigations into potential
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new tests, [4] [5] [6] [7] [8] [9] [10] serum biomarkers that are specific to CE in dogs have not yet been identified.
Citrulline, a nondietary amino acid involved in intermediary metabolism, is produced almost exclusively by the enterocytes of the small intestinal mucosa, and is a potential biomarker in intestinal disease. Circulating citrulline is dependent on de novo synthesis, as it is not found in food (except for watermelons). Therefore, decreased serum or plasma citrulline concentration corresponds to a reduction in functioning enterocyte mass. 11 In human medicine, citrulline is considered to be a reliable biomarker of remnant small intestinal enterocyte mass and absorptive capacity, independent of intestinal inflammation. 12 It is used to determine, quantitatively, intestinal epithelial integrity at the enterocyte level and is not greatly influenced by nutritional status or systemic inflammatory status. 11 Decreased plasma citrulline concentration correlates with reduced enterocyte mass in short bowel syndrome, [13] [14] [15] villous atrophy states, 16 and during follow-up of patients after small bowel transplantation. 17 Various cut-offs are employed in humans to quantify the degree of intestinal failure and are useful in predicting prognosis where there is intestinal compromise. 18, 19 To date, there have been few studies of citrulline in chronic intestinal diseases of dogs. 20, 21 Therefore, the aims of our study were to determine the value of citrulline as a biomarker in canine CE. The hypothesis was that serum citrulline concentration in dogs with CE will differ between dogs that respond to dietary management (adverse food reaction), those that have ARD, and those that have idiopathic IBD.
| M A TE RI A L S A ND M E TH ODS

| Dogs
This was a retrospective study involving client-owned dogs referred to of prednisolone, with the dose being subsequently reduced in dogs that responded well. This empirical approach using therapeutic trials is currently the most accurate way to determine a diagnosis in CE, and is in keeping with accepted criteria for the diagnosis of FRE, ARD, and IBD in dogs. 1, 22, 23 Dogs with IBD were further subdivided into those that responded well to immunosuppressive therapy and those that were refractory to treatment. Finally, all study dogs were also separately classified as PLE or non-PLE based on serum albumin concentration. The CIBDAI scoring index was used to quantify the severity of clinical signs and assess progression of disease. 
| Statistical analysis
Computer software was used to perform the analysis (GraphPad Prism 5.0). Continuous variables were assessed for normality using the 
| Comparison of citrulline concentration between dogs with CE and controls
Serum citrulline concentration was similar between dogs with CE (median 8.4 mg/mL, 5th-95th percentile 2.0-19.6) and controls (median 8.1 mg/mL, 5th-95th percentile 2.2-19.7; P 5 .91, Figure 1 ). for dogs that responded well, and median 7.7 mg/mL, 5th-95th percentile 1.4-16.8 for those that responded poorly, P 5 .79, Figure 2 ). 
| Comparison of citrulline concentration amongst CE dogs with different disease severity
| D ISC USSION
The main study conclusion was that serum citrulline concentration did not differ between dogs with various types of CE or between dogs with CE of different clinical severity. We had hypothesized that serum citrulline might help to predict response to treatment, as determined by response to sequentially performed therapeutic trials, but the fact that citrulline concentrations did not vary amongst treatment groups would suggest that this will not be possible. Another hypothesis was that serum citrulline concentrations might be useful in predicting whether dogs were likely to respond irrespective of treatment. However, serum citrulline concentrations did not differ between dogs that responded well to treatment and those that failed treatment or between those that were still alive at the end of the study period and those that had been euthanized because of CE. Moreover, there was no difference in serum citrulline concentration between dogs with CE and concurrent PLE and those with CE but no PLE, and no association was found between serum citrulline concentrations and disease severity, as determined by CIBDAI. The latter finding contrasts with the results of a previous, albeit smaller, study that did find a negative correlation between citrulline and the canine CE clinical activity index in 23 dogs with IBD, 21 and another study that showed a small but significant increase in citrulline in 10 dogs that received probiotics as treatment for IBD, at the same time that CIBDAI improved, suggesting that citrulline may have been low in affected dogs before treatment started. 20 The reason for differences between the studies is not clear, but might relate to differences in the populations studied, and diagnostic approach.
Therefore, although citrulline is a useful marker in human intestinal diseases as mentioned above, the results of our study do not support its use in the investigation and management of canine gastrointestinal disease. The reasons for such a species difference are not clear. The liver can contribute to circulating citrulline in dogs but not in humans. 26, 27 However, no dogs in our study were diagnosed with liver disease, and in another study canine parvoviral enteritis was associated with a drastic decrease in serum citrulline, even though acute liver damage was considered unlikely. 28 This result is consistent with the pathogenesis of canine parvoviral enteritis, in which extensive necrosis of enterocytes is known to occur, and suggests that in principle citrulline can be assayed in dogs as a marker of enterocyte mass.
The disorders in human medicine that are associated with reduced circulating citrulline involve significant loss or absence of functioning enterocytes, such as short bowel syndrome, [13] [14] [15] villous atrophy states, 16 intestinal failure associated with small bowel disruption and transient double enterostomy, 19 Crohn's disease with extensive bowel resection, 12 and critical illness. 18 Decreased circulating citrulline concentration might only occur when the loss of enterocytes is severe. 12, 29, 30 Citrulline concentration does not accurately indicate overall absorptive function, especially when there is not a large reduction in enterocyte mass. 11 If this is also true in dogs, it might explain why decreases in circulating citrulline were not seen in the dogs with CE in our study, in that the loss of functioning enterocyte mass might not have been severe enough to cause a detectable decrease in serum citrulline concentration. In humans, a citrulline generation test, in which the rate of conversion of glutamine into citrulline measured over time, has been suggested as a dynamic alternative to measurement of fasting serum citrulline concentration. It remains unknown whether this should become standard practice in human medicine 29 but to our knowledge, this test has not been assessed in client-owned dogs.
Our study has several limitations that should be considered. First, the cases assessed were from a referral-only population. Therefore, the findings might not be applicable to other populations, for example those visiting primary care practices. Second, the study was retrospective so that samples were not taken for the purpose of the study, and serum samples were stored for a variable time, until they could be analyzed in a batch. It is frequently considered that citrulline concentration is more stable and more reliably measured in plasma than in serum and it is unknown how this may have affected results. Serum samples were not deproteinized before storage. There was no correlation between time in storage and serum citrulline concentration (r 5 0.01, data not shown), but these results should be viewed with caution as citrulline degradation could possibly occur with storage at 2208C, and it is also possible that there could be liberation of citrulline from citrullinated proteins that might be present in the sample.
A third limitation, also related to the retrospective nature of the study, was the fact that clinical data were not recorded systematically for the direct purpose of the study. As a result, we were often reliant on the notes made by the attending clinician, and this might have led to errors, for example in how response to treatment was classified.
Some of the dogs diagnosed with IBD that responded poorly to treatment may have had alimentary lymphoma, given that histopathology can be unreliable in GI disease and that a small number of dogs did not have biopsies but were instead treated empirically. Further, since dogs with missing data were excluded, the population studied might not have been representative of all affected dogs. A future prospective study could be considered to confirm these findings and to examine changes of serum citrulline concentration over time.
Another limitation is that in humans, citrulline is considered as a marker of the severity of intestinal damage, correlated to the severity of the lesions and the length of gut affected, but this information was not available for all dogs in our study. Neither CIBDAI nor serum albumin have been correlated with the extent of intestinal damage and the true extent of the histopathological damage was not known for most dogs in our study, because most dogs underwent endoscopic biopsy and only a small part of the gut can be examined endoscopically.
| CON CL U S I ONS
In this retrospective study, serum citrulline concentration did not differ between dogs with CE and dogs attending the hospital for reasons unrelated to intestinal disease. There did not appear to be any relationship between serum citrulline and final diagnosis in canine CE. Therefore, use of serum citrulline cannot currently be recommended in the diagnostic investigation and clinical management of dogs with CE. 
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